Asset profile
HS-10353
Small molecule
Evidence outlook · results not reported
NCT05938179 · Major Depressive Disorder (MDD)
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT05938179: This is a well-designed randomized, quadruple-blind, placebo-controlled trial using a validated depression rating scale as its primary endpoint, but results have not yet been posted, so the outcome is unknown.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 2 direct rivals (same mechanism and indication), 10 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HS-10353: this drug | Phase 2 | Small molecule | GABA-A receptor | ||
| KH607 | Phase 3 | Small molecule | GABA-A receptor | ||
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2 | Small molecule | GABA-A receptor | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Valtoco) | Approved | Small molecule | GABA-A receptor | ||
| Ganaxolone | Approved | Small molecule | GABA-A receptor | ||
| Midazolam (Nayzilam) | Approved | Small molecule | GABA-A receptor, GABA-A receptor (benzodiazepine site) | ||
| Phenobarbital Sodium Injection (Sezaby) | Approved | Small molecule | GABA-A receptor | ||
| Stiripentol | Approved | Small molecule | GABA-A receptor | ||
| Diazepam (Libervant) | Phase 3 | Small molecule | GABA-A receptor | ||
| Staccato Alprazolam | Phase 3 | Combination | GABA-A receptor | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Cyclobenzaprine (Tonmya) | Approved | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) |
…and 57 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.